Google+ Facebook Twitter Twitter

Testosterone plea

Calls have been made for testosterone to be licensed in the UK for post-menopausal women.

Experts say the hormone is an important treatment for those experiencing reduced libido in midlife.

A taskforce brought together by the International Menopause Society (IMS) found testosterone could help women with hypoactive sexual desire dysfunction (HSDD) – characterised by a reduced interest in sex after menopause. HSDD affects about 32% of women in midlife, but testosterone for women is not licensed by the UK’s regulatory authorities.

The IMS statement on the hormone for women confirms post-menopausal women with HSDD can benefit from improved sexual desire, arousal, orgasm and pleasure, as well as reduced distress about sex.

Susan Davis, IMS President, said: “This statement reassures clinicians that a trial of testosterone therapy is appropriate for women with HSDD.”

Image credit | Shutterstock

Related Articles

One-to-one: COVID response controvery

We hear from Professor Sunetra Gupta – the theoretical epidemiologist who believes in herd immunity and doesn’t believe in the lockdown.

"Three times risk for frontline healthcare workers"

Frontline healthcare workers with adequate personal protective equipment (PPE) have a three-fold increased risk of a positive SARS-CoV-2 test, compared with the public.

Screening to improve mAb-based drugs

By screening potential monoclonal antibody (mAb)-based drugs solely on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study.